Mankind Pharma Ltd

Mankind Pharma Limited reported Q2 and H1 FY27 results with revenue of Rs. 4,338 crores, up 17% year-on-year, and EBITDA of Rs. 1,175 crores, up 27.2% year-on-year, with EBITDA margin improving by 210 bps to 27.1%. Domestic business excluding consumer healthcare grew 15.9% to Rs. 3,428 crores, driven by strong performance in Mankind and BSV specialty businesses. Chronic therapies outperformed the IPM by 1.1x, with cardio and anti-diabetes segments showing significant growth. The BSV portfolio continued its 20%+ growth momentum, supported by strong domestic and international sales. The consumer healthcare segment faced challenges, with revenue of Rs. 229 crores impacted by slower industry offtake and regional issues in East and South, though market share in key brands like Manforce and Preganews increased. Innovation initiatives, including the in-house JAK inhibitor MKP11093 and the acquisition of Armed Cell Therapeutics, were highlighted. Financially, gross margins increased by 90 bps to 72.2%, and EBITDA margins improved to 27.1%. The company emphasized strategic priorities such as expanding chronic and specialty therapies, enhancing international presence, and strengthening innovation pipelines. Management expressed confidence in sustaining growth and outperforming the IPM in the long term.

The document emphasizes strong revenue and EBITDA growth, outperformance in key therapeutic areas, and confidence in future strategies.